drugset / Trial / NCT01852890

Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I

NCT01852890

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a phase 1 (first in man) study testing the safety of adding high dose ascorbate (vitamin C) to standard radiation and chemotherapy for treatment of pancreatic cancer.

Timeline

Start
2014-01
Primary completion
2019-01-22
Completion
2025-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin C Other / unclassified 25 g Intravenous
Subject Vitamin C Other / unclassified 50 g Intravenous
Subject Vitamin C Other / unclassified 75 g Intravenous
Subject Vitamin C Other / unclassified 100 g Intravenous
Background Gemcitabine Small molecule 600 mg/m2 Intravenous

Indications